BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Liver cancer AND CDH1, uvomorulin, 999, P12830, ENSG00000039068, CDHE, Arc-1, UVO, LCAM, CD324, ECAD AND Treatment
80 results:

  • 1. Which factors predict tumor recurrence and survival after curative hepatectomy in hepatocellular carcinoma? Results from a European institution.
    Vaghiri S; Prassas D; Mustafov O; Kalmuk S; Knoefel WT; Lehwald-Tywuschik N; Alexander A; Dizdar L
    BMC Surg; 2024 Apr; 24(1):101. PubMed ID: 38589847
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Colorectal metastases with intrabiliary growth: incidence, treatment, and outcomes.
    Langella S; Armentano S; Russolillo N; Luzzi AP; Fontana AP; Daniele L; Ferrero A
    Updates Surg; 2024 Apr; 76(2):459-469. PubMed ID: 38483785
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Performance analysis of data resampling on class imbalance and classification techniques on multi-omics data for cancer classification.
    Yang Y; Mirzaei G
    PLoS One; 2024; 19(2):e0293607. PubMed ID: 38422094
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. DNMT3A Cooperates with YAP/TAZ to Drive Gallbladder cancer Metastasis.
    Xu S; Yuan Z; Jiang C; Chen W; Li Q; Chen T
    Adv Sci (Weinh); 2024 Apr; 11(16):e2308531. PubMed ID: 38380551
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Prognostic Value of Serum α-Fetoprotein Level as an Important Characteristic of Tumor Biology for Patients Undergoing liver Resection of Early-Stage Hepatocellular Carcinoma (BCLC Stage 0/A): A Large Multicenter Analysis.
    Yao LQ; Fan ZQ; Wang MD; Diao YK; Chen TH; Zeng YY; Chen Z; Wang XM; Zhou YH; Li J; Fan XP; Liang YJ; Li C; Shen F; Lv GY; Yang T
    Ann Surg Oncol; 2024 Feb; 31(2):1219-1231. PubMed ID: 37925654
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Diagnostic algorithm for subcentimeter hepatocellular carcinoma using alpha-fetoprotein and imaging features on gadoxetic acid-enhanced MRI.
    Huang P; Wu F; Hou K; Zhou C; Xiao Y; Wang C; Miao G; Yang C; Zeng M
    Eur Radiol; 2024 Apr; 34(4):2271-2282. PubMed ID: 37792079
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Impact of tumor suppressor genes inactivation on the multidrug resistance phenotype of hepatocellular carcinoma cells.
    Sanchez-Martin A; Sanchon-Sanchez P; Romero MR; Marin JJG; Briz O
    Biomed Pharmacother; 2023 Sep; 165():115209. PubMed ID: 37499450
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Construction and validation of a nomogram for hepatocellular carcinoma patients based on HCC-GRIm score.
    Yu X; Yang R; He Z; Li K; Zeng P
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):12013-12024. PubMed ID: 37421461
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Novel models by machine learning to predict prognosis of breast cancer brain metastases.
    Li C; Liu M; Zhang Y; Wang Y; Li J; Sun S; Liu X; Wu H; Feng C; Yao P; Jia Y; Zhang Y; Wei X; Wu F; Du C; Zhao X; Zhang S; Qu J
    J Transl Med; 2023 Jun; 21(1):404. PubMed ID: 37344847
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals.
    Watanabe T; Tokumoto Y; Joko K; Michitaka K; Horiike N; Tanaka Y; Hiraoka A; Tada F; Ochi H; Kisaka Y; Nakanishi S; Yagi S; Yamauchi K; Higashino M; Hirooka K; Morita M; Okazaki Y; Yukimoto A; Hirooka M; Abe M; Hiasa Y
    Sci Rep; 2023 Jun; 13(1):8992. PubMed ID: 37268672
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI.
    Huang P; Zhou C; Wu F; Xiao Y; Qian X; Wang Y; Yang C; Zeng M
    Eur Radiol; 2023 Apr; 33(4):2735-2745. PubMed ID: 36472696
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. A retrospective single-centered, comprehensive targeted genetic sequencing analysis of prognostic survival using tissues from Korean patients with metastatic renal cell carcinoma after targeted therapy.
    Kim SH; Park J; Park WS; Hong D; Chung J
    Investig Clin Urol; 2022 Nov; 63(6):602-611. PubMed ID: 36347549
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Interstitial Brachytherapy of the liver for Renal Cell Carcinoma: ADC Measurements Do Not Predict Overall Survival.
    Thormann M; Heitmann F; Wrobel V; March C; Pech M; Surov A; Damm R; Omari J
    In Vivo; 2022; 36(6):2945-2951. PubMed ID: 36309358
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric cancer.
    Peng K; Zhang F; Wang Y; Sahgal P; Li T; Zhou J; Liang X; Zhang Y; Sethi N; Liu T; Zhang H; Bass AJ
    Clin Cancer Res; 2023 Jan; 29(1):197-208. PubMed ID: 36278961
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Development and validation of a clinical-radiomics model to predict recurrence for patients with hepatocellular carcinoma after curative resection.
    Ren Y; Bo L; Shen B; Yang J; Xu S; Shen W; Chen H; Wang X; Chen H; Cai X
    Med Phys; 2023 Feb; 50(2):778-790. PubMed ID: 36269204
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Hypothyroidism has a protective causal association with hepatocellular carcinoma: A two-sample Mendelian randomization study.
    Lu L; Wan B; Li L; Sun M
    Front Endocrinol (Lausanne); 2022; 13():987401. PubMed ID: 36246884
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. A comparison of the simultaneous, liver-first, and colorectal-first strategies for surgical treatment of synchronous colorectal liver metastases at two major liver-surgery institutions in Sweden.
    Frühling P; Strömberg C; Isaksson B; Urdzik J
    HPB (Oxford); 2023 Jan; 25(1):26-36. PubMed ID: 36167765
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Segmentation of liver tumors with abdominal computed tomography using fully convolutional networks.
    Chen CI; Lu NH; Huang YH; Liu KY; Hsu SY; Matsushima A; Wang YM; Chen TB
    J Xray Sci Technol; 2022; 30(5):953-966. PubMed ID: 35754254
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Surgical resection versus radiofrequency ablation for early recurrent hepatocellular carcinoma.
    Shi T; Xu C; Feng Y; Wei Y; Lv H; Zhu Q
    Eur J Gastroenterol Hepatol; 2022 Aug; 34(8):844-851. PubMed ID: 35694799
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Cost-Effectiveness of Donafenib as First-Line treatment of Unresectable Hepatocellular Carcinoma in China.
    Guan H; Wang C; Zhao Z; Han S
    Adv Ther; 2022 Jul; 39(7):3334-3346. PubMed ID: 35644019
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.